Novavax jab first to protect against RSV


Sign up online today & collaborate

or click here to find out more

Novavax jab first to protect against RSV


Date: 12/08/2015

A vaccine created by Novavax has become the first to show efficacy in protecting again the ultra common respiratory syncytial virus, a major respiratory pathogen in infants, children, and adults around the globe.

Data from a Phase II trial of the jab show statistically significant efficacy in the prevention of all symptomatic RSV disease (44%) and RSV disease with symptoms of lower respiratory tract infection (46%) in older adults.

For more click here

Source: PharmaTimes

© Catalyst Innovation Portal 2019